Novel therapeutic approaches in chronic myeloid leukemia.
Leuk Res
; 91: 106337, 2020 04.
Article
em En
| MEDLINE
| ID: mdl-32200189
ABSTRACT
The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment. Although patients with CML generally do well under TKI therapy, there is a subgroup of patients who are resistant and/or intolerant to TKIs. In these group of patients, there is the need of additional treatment strategies. In this review, we provide an update on the current knowledge of these novel treatment approaches that can be used alone and/or in combination with TKIs.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Proteínas de Fusão bcr-abl
/
Resistencia a Medicamentos Antineoplásicos
/
Terapia de Alvo Molecular
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Leuk Res
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Turquia